Cyclerion Therapeutics Files 8-K
Ticker: CYCN · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-actions, financial-reporting
Related Tickers: CYCN
TL;DR
Cyclerion filed an 8-K on June 14th for votes and financials - details to follow.
AI Summary
Cyclerion Therapeutics, Inc. filed an 8-K on June 14, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details on the votes or financial statements themselves, but indicates their submission.
Why It Matters
This filing indicates that Cyclerion Therapeutics has submitted important corporate actions and financial information to the SEC, which could impact investor understanding of the company's status.
Risk Assessment
Risk Level: low — This is a routine filing to report on corporate actions and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of Cyclerion Therapeutics' security holders?
The filing indicates that matters were submitted to a vote, but does not specify what those matters were.
What financial statements are being filed with this 8-K?
The filing states that financial statements are being filed, but does not list the specific statements or the period they cover.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated June 14, 2024.
What is Cyclerion Therapeutics' principal executive office address?
The principal executive offices are located at 245 First Street, 18th Floor, Cambridge, Massachusetts 02142.
What is the registrant's telephone number?
The registrant's telephone number is (857) 327-8778.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-14 16:05:32
Filing Documents
- d811748d8k.htm (8-K) — 36KB
- 0001193125-24-161591.txt ( ) — 160KB
- cycn-20240614.xsd (EX-101.SCH) — 3KB
- cycn-20240614_lab.xml (EX-101.LAB) — 18KB
- cycn-20240614_pre.xml (EX-101.PRE) — 11KB
- d811748d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cyclerion Therapeutics, Inc. Dated: June 14, 2024 By: /s/ Regina Graul Name: Regina Graul Title: President